靶向前列腺特异性膜抗原的68Ga-NGUL PET/CT在健康志愿者和前列腺癌患者中的I期临床试验
这项前瞻性、开放标签、单臂I期临床试验纳入6名健康成年男性和6名转移性前列腺癌患者,评估68Ga-NGUL的安全性、辐射剂量学及病灶检出率。结果显示无药物相关不良事件,健康成人中肾脏摄取最高,中位有效剂量系数为0.025 mSv/MBq;在转移性前列腺癌患者中,68Ga-NGUL PET/CT检出199/229(86.9%)可疑病灶,常规影像(CT和骨闪烁显像)检出114/229(49.8%)。
要点
- 68Ga-NGUL PET/CT在转移性前列腺癌中检出199/229(86.9%)可疑病灶,高于常规影像的114/229(49.8%)。
- 健康成人中68Ga-NGUL快速分布,肾脏摄取最高,中位有效剂量系数为0.025 mSv/MBq。
- 所有12名参与者完成试验,未观察到药物相关不良事件。
核心结论
- 68Ga-NGUL可安全应用于临床,对前列腺癌转移灶定位的检出率高于常规影像,是前列腺癌成像的有价值选择。
研究设计与样本
- 前瞻性、开放标签、单臂I期临床试验,两个队列共12名参与者(6名健康成年男性,年龄31-32岁;6名转移性前列腺癌患者,年龄57-81岁);68Ga-NGUL给药剂量为2 MBq/kg(96-165 MBq),行PET/CT多时间点扫描;健康成人用OLINDA/EXM软件计算器官吸收剂量和有效剂量;患者中比较筛查期(招募后一个月内)68Ga-NGUL PET/CT与常规影像(CT和骨闪烁显像)的可疑病灶检出率。
关键影像表现/征象
- 健康成人中68Ga-NGUL快速分布,肾脏摄取最高,膀胱累积活性贡献最大。
- 转移性前列腺癌患者中,68Ga-NGUL PET/CT检出199个(86.9%)可疑病灶,常规影像检出114个(49.8%)可疑病灶。
诊断标准与关键数值
- 健康成人中68Ga-NGUL的中位有效剂量系数为0.025 mSv/MBq。
- 转移性前列腺癌患者中,68Ga-NGUL PET/CT对可疑病灶的检出率为86.9%(199/229),常规影像(CT和骨闪烁显像)为49.8%(114/229)。
临床应用与阅片要点
- 68Ga-NGUL PET/CT可用于前列腺癌转移灶的定位,其检出率高于常规影像。
- 健康成人中肾脏摄取最高,膀胱累积活性贡献最大,阅片时需注意泌尿系统生理性摄取。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: 68Ga-NGUL is a novel prostate-specific membrane antigen (PSMA)-targeting tracer based on Glu-Urea-Lys derivatives conjugated to a 1,4,7-triazacyclononane-N, N', N″-triacetic acid (NOTA) chelator via a thiourea-type short linker. This phase I clinical trial of 68Ga-NGUL was conducted to evaluate the safety and radiation dosimetry of 68Ga-NGUL in healthy volunteers and the lesion detection rate of 68Ga-NGUL in patients with prostate cancer.
MATERIALS AND METHODS: We designed a prospective, open-label, single-arm clinical trial with two cohorts comprising six healthy adult men and six patients with metastatic prostate cancer. Safety and blood test-based toxicities were monitored throughout the study. PET/CT scans were acquired at multiple time points after administering 68Ga-NGUL (2 MBq/kg; 96-165 MBq). In healthy adults, absorbed organ doses and effective doses were calculated using the OLINDA/EXM software. In patients with prostate cancer, the rates of detecting suspicious lesions by 68Ga-NGUL PET/CT and conventional imaging (CT and bone scintigraphy) during the screening period, within one month after recruitment, were compared.
RESULTS: All 12 participants (six healthy adults aged 31-32 years and six prostate cancer patients aged 57-81 years) completed the clinical trial. No drug-related adverse events were observed. In the healthy adult group, 68Ga-NGUL was rapidly distributed, with the highest uptake in the kidneys. The median effective dose coefficient was calculated as 0.025 mSv/MBq, and cumulative activity in the bladder had the highest contribution. In patients with metastatic prostate cancer, 229 suspicious lesions were detected using either 68Ga-NGUL PET/CT or conventional imaging. Among them, 68Ga-NGUL PET/CT detected 199 (86.9%) lesions and CT or bone scintigraphy detected 114 (49.8%) lesions.
CONCLUSION: 68Ga-NGUL can be safely applied clinically and has shown a higher detection rate for the localization of metastatic lesions in prostate cancer than conventional imaging. Therefore, 68Ga-NGUL is a valuable option for prostate cancer imaging.
引用
- Suh, Ryoo, Kang, et al. Phase I Clinical Trial of Prostate-Specific Membrane Antigen-Targeting 68Ga-NGUL PET/CT in Healthy Volunteers and Patients with Prostate Cancer. Korean J Radiol. 2022. PMID: 35762185. doi:10.3348/kjr.2022.0176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。